 NOVATO, Calif., Feb. 17, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the companys Chief Executive Officer and President, will present at the following upcoming investor conferences: 